Preclinical Molecular Imaging Group

Dr Gabriela Kramer-Marek’s group uses cutting-edge biomedical imaging techniques to gain information about the way particular genes drive cancer progression.

Our group’s long-term goal is to develop specific biomarkers for detecting cancers and to evaluate these biomarkers in pre-clinical cancer models

Notwithstanding the remarkable clinical success of mAb-based treatment regimens, not all patients benefit from them. This can be attributed, at least in part, to the complexity of the tumour microenvironment and its considerable heterogeneity both in terms of the tumour and non-tumour cell components. These phenomena represent a huge challenge in identifying predictive biomarkers and stratifying patient populations for personalised therapy approaches.

Therefore, there is an urgent need to develop assays that will help in three ways:

  1. accurate patient selection
  2. understanding intrinsic resistance mechanisms or the emergence of acquired resistance following treatment initiation and
  3. choosing the most effective combination regimen in circumstances in which single-agent therapies are insufficiently effective.

Currently, the baseline expression level of antigens targeted by therapeutic mAbs can be analysed by methods such as: immunohistochemistry (IHC), flow cytometry, proteomics, or next-generation sequencing of tumour tissues acquired at diagnostic biopsy or intra-operatively. These techniques aid our understanding of how cancer cells adapt to treatment and become resistant, but such methods are inherently invasive, prone to sampling errors caused by inter- and intra-tumour heterogeneity of receptor expression within analysed biopsy specimens and do not lend themselves readily to repeated sampling.

Positron emission tomography (PET), using radiolabelled mAbs, antibody fragments or engineered protein scaffolds (immuno-PET), has the potential to acquire information non-invasively and can be highly complementary to analyses based on tissue acquisition. Accordingly, immuno-PET agents might accurately identify the presence and accessibility of the target and provide a rapid assessment of tumour response to a variety of treatments in a timely fashion (e.g. within 1-2 weeks of treatment initiation).

Furthermore, immuno-PET agents can provide information about the heterogeneity of both target expression and therapeutic response, which are increasingly recognised as key factors in treatment resistance. This especially relates to patients with advanced disease in whom target expression may vary from site to site and a biopsy of a single local or metastatic deposit may not accurately reflect the situation across the entire disease burden. Although introduction of immuno-PET into routine clinical practice may add complexity and increase costs, with appropriate use this imaging modality has the potential to identify patients likely to benefit from therapy and assess the efficacy of novel target-specific drugs.

Against this background, our research focuses on the development and characterisation of targeted-PET radiotracers, including protein-based theranostic agents that enable smart monitoring of immunotherapies and expand opportunities for personalised medicine approaches.

Early diagnosis and individualized therapy have been recognized as crucial for the improvement of cancer treatment outcome. While proper molecular characterization of individual tumour types facilitates choice of the right therapeutic strategies, early assessment of tumour response to therapy could allow the physicians to discontinue ineffective treatment and offer the patient a more promising alternative. Therefore, the role of molecular imaging in elucidating molecular pathways involved in cancer progression and the ability to select the most effective therapy based on the unique biologic characteristics of the patient and the molecular properties of a tumour are undoubtedly of paramount importance.

The mission of this group is to investigate innovative imaging probes and apply them to novel orthotopic or metastatic models that are target driven, to gain information of the way particular oncogenes drive cancer progression through signalling pathways that can be imaged in vivo and, correlate it with target level ex vivo. Such an approach enables non-invasive assessment of biochemical target levels, target modulation and provides opportunities to optimize the drug dosing for maximum therapeutic effect, which leads to the development of better strategies for the more precise delivery of medicine.

The long term goal of our research is to develop specific imaging cancer biomarkers, especially for positron emission tomography (PET) as well as optical imaging and, evaluate these biomarkers in pre-clinical cancer models. Significant efforts are directed towards validating biomarkers for early prediction of treatment response, with the focus on new targeted therapies (such as inhibition of cell signalling pathways).

Our initial portfolio of imaging agents include radiolabelled affibody molecules, TK inhibitors and, conventional tracers that monitor universal markers of tumour physiology.

We are actively supported by other groups from the Division of Radiotherapy and Imaging as well as the Division of Cancer Therapeutics. Moreover, our close association with The Royal Marsden NHS Foundation Trust enables rapid translation of our research to early clinical studies and ensures a fast transition of know-how from the research laboratory to the patient bedside.

Dr Gabriela Kramer-Marek

Group Leader:

Preclinical Molecular Imaging Gabriela Kramer-Marek

Dr Gabriela Kramer-Marek is investigating new ways of molecular imaging in order to predict an individual patient’s response to treatment. Before moving to the ICR, she developed a new approach for non-invasive assessment of HER2 expression in breast cancer.

Researchers in this group

.

Phone: 020 3437 6376

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6785

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6857

Email: [email protected]

Location: Sutton

.

Phone: 020 3437 4549

Email: [email protected]

Location: Sutton

Dr Gabriela Kramer-Marek's group have written 63 publications

Most recent new publication 10/2024

See all their publications

Recent discoveries from this group

14/02/25

Image of human melanoma tissue, with melanoma cells in green and purple extracellular matrix fibres arranged perpendicular at the border of the tumour. Credit Oscar Maiques Carlos

Scientists have discovered a new way to predict which tumours will become aggressive before they metastasise and spread around the body.

New research, published in Nature Communications, reveals how cancer cells are altered by their surroundings, enabling them to change their shape and break out of a tumour.  The discovery paves the way for treatments that will tackle cancer before it can spread.

Scaffolding around tumours acts as a 'roadmap'

Tumours are held together by a structure called the extracellular matrix (ECM), which acts like the scaffolding around a building under construction.

A team from The Institute of Cancer Research, London, and Barts Cancer Institute at Queen Mary University of London (BCI-QMUL), discovered how cancer cells use the layout of this scaffolding structure as a ‘roadmap’ to leave the tumour. They found that the ECM triggers changes within the cancer cells themselves – altering their shape and boosting their ability to travel to different parts of the body.

This breakthrough, which is the culmination of almost a decade of research that began at King’s College London, means that aggressive tumours that are likely to metastasise can now more easily be identified at an earlier stage – allowing clinicians to tailor treatment sooner. Drugs are currently in development to target the ECM’s layout, as well as the genes that drive these cell shape changes – which could stop cancer in its tracks before it can escape the tumour and spread.

Extracellular matrix provides the 'tracks' for cells to follow

The team, funded by Cancer Research UK and Barts Charity, and working in the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research (ICR), looked at tumour tissue from 99 patients with melanoma skin cancer and breast cancer.

They saw that the ECM was laid out differently in three distinct areas of the tumour. Like scaffolding, the ECM is made up of a number of components, including pole-like fibres. At the centre of the tumour, the fibres were spread out and disorganised, whilst at the border they were tightly packed and thicker. At the outermost border of the tumour, the fibres were arranged pointing away from the tumour – providing the ‘tracks’ for the cancer cells to follow as they escape from the tumour. At this outermost border of the tumour, the cancer cells were rounded – a more invasive cell shape.

Aggressive cells have a different expression of genes

The team tested whether the conditions at the border of the tumour make the cancer cells more aggressive. They grew melanoma cancer cells in a model of these conditions and injected them into mice. Cancer cells grown in these conditions were more likely to spread to the lungs and metastasise than melanoma cells grown in control conditions with disorganised fibres.

The researchers saw differences in the type of genes present in the cells depending on where in the tumour they came from. Cells at the border of the tumour had more genes linked to cell migration, rounding of the cell shape, and inflammation – all making the cells more aggressive and likely to survive. The team also saw an increase in the expression of genes for enzymes that impact the organisation of the matrix – highlighting how cancer cells corrupt their surroundings to break out of the tumour.

Comparing these findings to cancers from patients with 14 different tumour types, including melanoma, breast, pancreatic, lung cancer and glioblastoma – an aggressive brain cancer – the researchers found that a higher presence of these genes was associated with a shorter survival time.

Treating cancer before it spreads

The researchers say that these findings open new avenues for treatment to tackle cancer before it can spread, such as drugs targeting lysyl oxidase (LOX), which are already in clinical trials for other conditions. These drugs work by targeting an enzyme that stabilises the matrix, which is found more abundantly in the border region of tumours. The ICR has previously carried out research to show the possibility of targeting LOX in cancer treatment.

Professor Victoria Sanz Moreno, Professor of Cancer Cell and Metastasis Biology at The Institute of Cancer Research, London, who led the study said:

“Our research has uncovered the roadmap that cancer cells follow to break out of a tumour, enabling it to cause a secondary tumour elsewhere in the body. Now that we understand this roadmap, we can look to target different aspects of it, to stop aggressive cancers from spreading.

“The fibres in the structure surrounding the tumour are denser and are laid out like a path for cells to follow, the further out at the border of the tumour that we look. Future research should explore ways to target this arrangement, to prevent cancer cells from being able to escape and follow this path. We may also find that targeting this dense arrangement of fibres means other drugs can reach cancer cells more easily, which could improve how well treatments work.” 

'What's on the outside of the tumour is just as important as what's in the centre'

Dr Oscar Maiques, Group Leader and Lecturer in Digital Pathology at the Barts Cancer Institute at Queen Mary University of London, said:

“This study is the culmination of almost a decade of research to understand how cancer cells interact with their surroundings, known as the extracellular matrix.

“Importantly, we see that various regions of the tumour hold different information about that cancer’s future behaviour. When clinicians biopsy the tumour, our research shows that what’s on the outside of the tumour is just as important as what’s in the centre – as this holds crucial information about whether a cancer is likely to spread.”

Cancer operates in a 'complex ecosystem'

Professor Kristian Helin, Chief Executive at The Institute of Cancer Research, London, said:

“We know that most cancer deaths occur because cancer has spread from the original tumour to other parts of the body, at which point it becomes much harder to treat. To develop better treatments for cancer patients, we must understand the complex ecosystem in which it operates. This research reveals how a tumour’s surroundings alter the cancer cells within it and enable them to spread. I hope that further research will lead to the development of treatments that target these interactions and prevent cancer from spreading.”

Dr Iain Foulkes, Executive Director of Research and Innovation at Cancer Research UK, said:

“Understanding how cancer spreads is crucial to finding treatments which can stop the disease advancing further. This research shows how much cancer relies on the scaffolding around it to move and spread elsewhere. Cutting down this scaffolding could deprive cancer of opportunities to spread and improve the chances of successful treatment, and I look forward to further research which hopes to achieve this aim.”